Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From Virtual Screening to Cell Phenotype: 4-Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer.

Chemical biology & drug design - 1 Jun 2026

Ferreira Sandra, Santos Beatriz, Tavares Matilde, Holota Serhii, Khylyuk Dmytro, Lesyk Roman, Finyuk Natalia, Dos Santos Daniel J V A, Díaz-Lanza Ana M, Costa João G, Saraiva Nuno, Fernandes Ana S

Abstract excerpt

Lysyl Oxidases (LOXs) catalyse elastin and collagen cross-linking in the extracellular matrix and have been implicated in cancer cell progression and metastases, particularly in breast cancer. In this study, we sought small-molecule inhibitors of LOXL2 using a library of 4-thiazolidones supported by molecular docking. Five candidates were prioritised, with Les 5740 displaying the highest LOXL2 inhibitory activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Oxidoreductases
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Movement

Share to Enzyme Inhibitors

Share to Molecular Docking Simulation

Share to Thiazolidines

Share to Triple Negative Breast Neoplasms

Share to Tubulin

Source

Identifiers

PMID: 42206657
DOI: 10.1111/cbdd.70320

Genes

LOXL2
MB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From Virtual Screening to Cell Phenotype: 4-Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer.PMID 42206657Read ↗

Lysyl Oxidases Expression and Breast Cancer Progression: A Bioinformatic AnalysisSemantic proximity Read ↗

LOX inhibition disrupts a collagen-integrin–MYC axis as a translatable targeting strategy in invasive lobular carcinomaSemantic proximity Read ↗

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.Semantic proximity Read ↗

Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3Semantic proximity Read ↗

Triptonide Effectively Inhibits Triple-Negative Breast Cancer Metastasis Through Concurrent Degradation Of Twist1 And Notch1 OncoproteinsSemantic proximity Read ↗

Targeting the lysyl oxidases in tumour desmoplasiaSemantic proximity Read ↗

Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancerSemantic proximity Read ↗

Comparative Evaluation of the Cytotoxicity of Doxorubicin in BT-20 Triple-Negative Breast Carcinoma Monolayer and Spheroid CulturesSemantic proximity Read ↗

A Phenotypic Cell-Binding Screen Identifies a Novel Compound Targeting Triple-Negative Breast Cancer.Semantic proximity Read ↗

Characterization of TR-107, a Novel Chemical Activator of the Human Mitochondrial Protease ClpPSemantic proximity Read ↗

Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transitionSemantic proximity Read ↗

Topsentinol L Trisulfate, a new Marine Natural Product, that Targets Basal-like and Claudin-low Breast CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.